Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising ...

Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...

Akeso enrols first patient in phase Ia trial for AK146D1, a bispecific ADC targeting Trop2 and Nectin4: Hong Kong Monday, July 7, 2025, 18:00 Hrs [IST] Akeso, Inc., a leading biop ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertise ...